Physician profile
Michael Cook
NPI 1649245317
$3,126.65
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,023 · 2020: $428 · 2021: $493 · 2022: $551 · 2023: $633.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $633.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $374.33 | 2019-2023 | Evusheld, Farxiga |
| Amgen INC. | $279.84 | 2019-2023 | Tavneos, Parsabiv |
| Vifor Pharma, INC. | $263.79 | 2019-2023 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $240.88 | 2019-2023 | Jynarque |
| Mallinckrodt Enterprises LLC | $178.75 | 2019 | |
| Philips North America LLC | $172.90 | 2019-2020 | |
| Bard Peripheral Vascular, INC. | $160.84 | 2019-2022 | |
| Abbott Laboratories | $155.05 | 2019-2023 | Jeti |
| Glaxosmithkline, LLC. | $139.13 | 2019-2023 | Jesduvroq, Benlysta |
| Fresenius USA Marketing, INC. | $131.46 | 2019-2022 | |
| Nxstage Medical, INC. | $122.80 | 2023 | Nxstage System One |
| Mallinckrodt Hospital Products INC. | $121.34 | 2020-2022 | |
| Horizon Therapeutics Plc | $119.13 | 2020-2023 | Krystexxa |
| W. L. Gore & Associates, INC. | $106.28 | 2020-2023 | Gore Viabahn Endoprosthesis, Gore Viabahn Endoprosthesis With Heparin, Gore Propaten Vascular Graft |
| Calliditas Therapeutics US INC. | $101.19 | 2022-2023 | Tarpeyo |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $63.09 | 2019-2023 | |
| Genzyme Corporation | $49.54 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $48.01 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $47.06 | 2019-2021 | |
| Daiichi Sankyo INC. | $38.97 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $38.21 | 2022-2023 | Lupkynis |
| Alnylam Pharmaceuticals INC. | $35.10 | 2021-2023 | Onpattro |
| Opko Pharmaceuticals, LLC | $30.07 | 2020-2022 | |
| Vbi Vaccine (Delaware) INC. | $24.80 | 2023 | Prehevbrio |
| Ani Pharmaceuticals, INC. | $22.13 | 2022 | |
| Akebia Therapeutics INC | $16.10 | 2019 | |
| Lundbeck LLC | $15.69 | 2019 | |
| Medtronic, INC. | $15.42 | 2021 | |
| Travere Therapeutics, INC. | $14.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.